Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • Advanced therapies
  • Virology
  • Diagnostics
  • Biotherapeutics
  • Bacteriology
  • Analytical sciences
  • A to Z listing
  • Publications
  • Home  /  
  • Science and research  /  
  • Biotherapeutics  /  
  • Nanobodies  /  
  • SARS-CoV

SARS-CoV

Single‑domain antibodies (VHH nanobodies) generated from an immunised alpaca. The panel comprises SARS‑CoV‑2–specific VHHs against the pandemic Wuhan strain and subsequent variants as well as CoV‑1/2 cross‑reactive nanobodies against highly conserved elements of the S2 domain identified by yeast display deep mutational scanning.

Some of these nanobodies are featured in the following publication.

Ball CR, Ramage W, Mate R, Hufton SE. Susceptibility of broad reactivity nanobodies to resistance mutations in the S2 domain of SARS-CoV-2 predicted by yeast display deep mutational scanning. Front Immunol. 2026 Jan 12;16:1726449. doi: 10.3389/fimmu.2025.1726449.

For enquiries visit: Non-Exclusive Licensing Enquiry Form for Nanobodies

 
  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap